Table 1.
Phenotypic characteristics of the transconjugants of the eight carbapenem-resistant and colistin-resistant E. coli.
Antibiotics tested | Transconjugants selected by rifampin plus imipenem plus colistin | E. coli C600 | ||||||
---|---|---|---|---|---|---|---|---|
Minimum inhibitory concentration (μg/ml) | ||||||||
Cir007 1 | Cir012 | Cir020 | Cir033 | Cir035 | Cir100 | Cir115 | ||
Amikacin | > 32 (R1) | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | ≤ 8 (S) |
Gentamicin | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | ≤ 2 (S) |
Tobramycin | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | ≤ 2 (S) |
Ertapenem | > 2 (R) | > 2 (R) | > 2 (R) | > 2 (R) | > 2 (R) | > 2 (R) | 2 (R) | ≤ 0.25 (S) |
Imipenem | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | 1 (S) | 8 (R) | 0.5 (S) |
Meropenem | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | > 8 (R) | 1 (S) | 4 (R) | ≤ 0.13 (S) |
Cefazolin | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | 4 (S) |
Cefuroxime | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | 16 (R) |
Cefoxitin | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | > 16 (R) | 8 (S) |
Ceftazidime | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | ≤ 1 (S) |
Ceftriaxone | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | > 32 (R) | ≤ 1 (S) |
Cefepime | > 16 (R) | > 16 (R) | > 16 (R) | 16 (R) | > 16 (R) | 16 (R) | 8 (R) | ≤ 1 (S) |
Amoxicillin/clavulanate | > 32/16 (R) | > 32/16 (R) | > 32/16 (R) | > 32/16 (R) | > 32/16 (R) | 32/16 (R) | 32/16 (R) | ≤ 8/4 (S) |
Ampicillin/sulbactam | >16/8 (R) | >16/8 (R) | >16/8 (R) | >16/8 (R) | > 16/8 (R) | > 16/8 (R) | >16/8 (R) | 8/4 (S) |
Piperacillin/tazobactam | >64/4 (R) | >64/4 (R) | >64/4 (R) | >64/4 (R) | >64/4 (R) | >64/4 (R) | >64/4 (R) | ≤ 4/4 (S) |
Colistin | > 4 (R) | > 4 (R) | 4 (R) | 4 (R) | 4 (R) | > 4 (R) | > 4 (R) | ≤ 1 (S) |
Chloramphenicol | > 16 (R) | > 16 (R) | > 16 (R) | ≤ 4 (S) | ≤ 4 (S) | > 16 (R) | ≤ 4 (S) | ≤ 4 (S) |
Moxifloxacin | > 2 (R) | > 2 (R) | > 2 (R) | ≤ 0.5 (S) | ≤ 0.5 (S) | > 2 (R) | ≤ 0.5 (S) | ≤ 0.5 (S) |
Ciprofloxacin | > 4 (R) | > 4 (R) | > 4 (R) | ≤ 0.5 (S) | ≤ 0.5 (S) | 2 (I) | ≤ 0.5 (S) | ≤ 0.5 (S) |
Levofloxacin | > 8 (R) | > 8 (R) | > 8 (R) | ≤ 1 (S) | ≤ 1 (S) | 2 (S) | ≤ 1 (S) | ≤ 1 (S) |
Norfloxacin | > 8 (R) | > 8 (R) | > 8 (R) | ≤ 2 (S) | ≤ 2 (S) | 4 (S) | ≤ 2 (S) | ≤ 2 (S) |
Tetracycline | > 8 (R) | > 8 (R) | > 8 (R) | ≤ 2 (S) | ≤ 2 (S) | > 8 (R) | ≤ 2 (S) | ≤ 2 (S) |
Minocycline | 4 (S) | 4 (S) | 4 (S) | ≤ 1 (S) | 2 (S) | 16 (R) | 2 (S) | ≤ 1 (S) |
Trimethoprim/sulfamethoxazole | > 4/76 (R) | > 4/76 (R) | > 4/76 (R) | ≤1/19 (S) | ≤ 1/19 (S) | ≤ 1/19 (S) | ≤1/19 (S) | ≤ 1/19 (S) |
Aztreonam | ≤ 2 (S) | ≤ 2 (S) | ≤ 2 (S) | ≤ 2 (S) | ≤ 2 (S) | ≤ 2 (S) | ≤ 2 (S) | ≤ 2 (S) |
Fosfomycin | > 128 (R) | > 128 (R) | > 128 (R) | ≤ 16 (S) | ≤ 16 (S) | ≤ 16 (S) | > 128 (R) | ≤ 16 (S) |
Nitrofurantoin | ≤ 16 (S) | 32 (S) | ≤ 16 (S) | ≤ 16 (S) | ≤ 16 (S) | > 64 (R) | ≤ 16 (S) | ≤ 16 (S) |
Tigecycline | ≤ 1 (S) | ≤ 1 (S) | ≤ 1 (S) | ≤ 1 (S) | ≤ 1 (S) | ≤ 1 (S) | ≤ 1 (S) | ≤ 1 (S) |
1 Note: Cir007, Cir012, Cir020, Cir033, Cir035, Cir100, and Cir115 represent the transconjugant of RXD007, RXD012, RXD020, RXD033, RXD035, RXD100, and RXD115, respectively. R: Resistant; S: susceptible; I: intermediately resistant.